Category: Health Science
-
![Diagnos (ADK.V) Announces Pilot with Opticalia in Spain]()
Diagnos (ADK.V) Announces Pilot with Opticalia in Spain
Diagnos (ADK.V), a leader in early detection announced today that it has signed a pilot in Spain with three franchisees from Opticalia Group. “The campaign begins with the request for a previous appointment through the web or at the optician itself, where patients will register in order of arrival and a free retinography will be…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
![Diagnos (ADK.V) opens A.I screening clinics in diabetes-ravaged Saudi Arabia]()
Diagnos (ADK.V) opens A.I screening clinics in diabetes-ravaged Saudi Arabia
On July 22, 2021 Diagnos (ADK.V) announced the official opening of the initial clinics at the Magrabi Hospital in Saudi Arabia. DIAGNOS specialises in early detection of health problems based on its FLAIRE artificial intelligence (AI) platform. The FLAIRE platform is used in applications such as CARA (Computer Assisted Retina Analysis). CARA’s artificial intelligence-based image…
-
![XPhyto Therapeutics (XPHY.C) Signs Acquisition Agreement with 3a-Diagnostics, Enters Biosensor Market]()
XPhyto Therapeutics (XPHY.C) Signs Acquisition Agreement with 3a-Diagnostics, Enters Biosensor Market
XPhyto Therapeutics (XPHY.C) announced today that it has signed a definitive agreement for the acquisition of 3a-Diagnostics GmhB, Frickenhausen, Germany, XPhyto’s exclusive diagnostic development partner. “We have collaborated closely with the 3a-diagnostics team on several diagnostics products and have found them to be a highly innovative and focused partner. The successful development and recent launch…
-
![Bioasis Technologies (BTI.V) stock is on the move – following scientific validation of xB3 platform]()
Bioasis Technologies (BTI.V) stock is on the move – following scientific validation of xB3 platform
Bioasis Technologies’ (BTI.V) xB3 platform is designed to deliver therapeutics across the blood brain barrier. BTI’s proprietary tech is relevant to the treatment of brain cancers and neurodegenerative diseases. Investing in small-cap pharmaceutical companies requires patience. Not every product in the pipeline pans out. Some trials have disappointing outcomes. Many investors can’t handle the zigs…
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
-
![Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?]()
Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?
“Suicide Opportunity” I can’t remember what company it was, maybe MindMed, but one of their early pitch decks had a page titled ‘Suicide Opportunity’. Yesterday I wrote an article outlining how Seelos Therapeutics was targetting suicide with ketamine-based treatments and it reminded me for a moment of that pitch deck. To note, Seelos didn’t word…
-
![Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan]()
Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name Trecondyv®. It’s used in combination with another drug called fludarabine as part of a conditioning treatment prior to allogeneic hemapoietic stem cell transplantation. The treatment clears the…
-
![Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal]()
Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according to a press release. The terms of the agreement give Bioasis the ability to issue convertible securities up to $10 million with proceeds going to general…
-
![Bioasis Technologies (BTI.V) and the painful price of private sector science]()
Bioasis Technologies (BTI.V) and the painful price of private sector science
Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…
